[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608597":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":56,"collaborators":18,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":18,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interventional group","EXPERIMENTAL","Patients will receive intravenous Tenecteplase 0.25 mg\u002Fkg body-weight up to a maximum of 25mg before the interhospital transfer or the physician departure. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs or physician travelling for thrombectomy should be initiated immediately after Tenecteplase administration.",[13],"Drug: Tenecteplase thrombolysis",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Patients will receive standard treatment and be directly transferred to ECCs or transfer physician for EVT according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tenecteplase thrombolysis","Patients will receive intravenous Tenecteplase 0.25 mg\u002Fkg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.",[9],[26],"rhTNK-tPA",[28],{"name":29,"affiliation":5,"role":30},"Junwei Hao, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","01083198277","haojunwei@vip.163.com",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Gaoting Ma, MD","01083198082","demo_doctor@163.com",[41],{"facility":42,"status":43,"city":44,"state":18,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Xuanwu Hospital, Capital Medical University","RECRUITING","Beijing","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":37,"role":33,"phone":55,"phoneExt":18,"email":39},"010-83198082",{"type":57,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100608597","phase-4-tenecteplase-before-interhospital-transfer-in-acute-basilar-artery-occlusion-at-45-to-24-hours-100608597",false,"NCT07203625","Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","Intravenous Tenecteplase Before Interhospital Transfer for Thrombectomy in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","OPTION-2","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients presenting with posterior circulation ischemic stroke symptoms due to BAO;\n* BAO confirmed by computed tomographic angiography (CTA)\u002F magnetic resonance angiography (MRA);\n* Time from AIS symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the onset of acute symptoms leading to the clinical diagnosis of basilar artery occlusion (BAO) not considering the time of any preceding minor prodromal symptoms (such as isolated vertigo, diplopia or sensory changes) as onset time or, if not known, the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Baseline National Institute of Health Stroke Scale (NIHSS) score obtained prior to randomization ≥6;\n* Functionally independent (modified Rankin Scale \\[mRS\\] 0-2) prior to stroke onset;\n* Intended to transfer for thrombectomy. Two paradigms are allowed in this study: (1)transferring patients to ECC (patient transfer); (2)travelling neurointerventionist to nECC (physician transfer);\n* Written informed consent from patients or legally responsible representatives\n\nExclusion Criteria:\n\n* Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) \\\u003C 6 on computed tomography (CT)\u002FCTA-Source Images\u002FMRI with diffusion-weighted imaging (DWI)\n* CT\u002FMR shows evidence of intracranial hemorrhage and tumor (except small meningioma)\n* Complete cerebellar infarct on CT\u002FMRI with significant mass effect and compression of the 4th ventricle\n* Bilateral extensive brainstem infarction on CT\u002FMRI\n* Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA\u002FMRA\u002FDSA (patients with a history of occlusion of anterior circulation more than three months ago can be included)\n* Treatment with a thrombolytic within the last 72 hours or intention to receive intravenous thrombolysis\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase\n* Any other contra-indication for intravenous thrombolysis except for the time criteria\n* Known hereditary or acquired hemorrhagic diathesis\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, international normalized ratio (INR) \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if use of heparin\u002Fheparinoid within the last 24 hours\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months\n* Severe, uncontrolled hypertension (systolic blood pressure \\>185mmHg or diastolic blood pressure \\>110mmHg)\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl\n* Baseline platelet count \\\u003C100,000\u002FμL\n* Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \\\u003C30mL\u002Fmin or serum creatinine \\>220mmol\u002FL (2.5mg\u002FdL)\n* Known severe, life-threatening allergy (more severe than skin rash) to contrast agents\n* Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery\n* Known diagnosis or clinical suspicion of cerebral vasculitis\n* Known diagnosis or clinical suspicion of endocarditis\n* Pregnancy or lactating;\n* Other serious, advanced or terminal illness with life expectancy less than 6 months\n* Current participation in any investigational study that may confound outcome assessment of the study\n* Any condition that, in the judgement of the investigator, is inappropriate for participation in the trial or could impose hazards to the patient (e.g. inability to understand and\u002For follow the study procedures and\u002For follow-up due to mental disorders, cognitive or emotional disorders)","ALL","18 Years",{"count":69,"type":70},316,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.",[76,77],"Acute Ischemic Stroke","Basilar Artery Occlusion",[79,80,81],"basilar artery occlusion","thrombolysis","interhospital transfer","2026-03-16",{"date":84,"type":85},"2026-03-19","ACTUAL",{"date":87,"type":85},"2026-01-20",{"date":89,"type":70},"2027-12-31",{"name":5,"class":6},1]